Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics
Quantum-Si (Nasdaq: QSI) has released a new preprint demonstrating the integration of their benchtop Platinum® instrument with protein barcoding technology. The study showcases a novel workflow that enhances multiplexed protein analysis with improved sensitivity and accessibility compared to traditional methods like mass spectrometry.
The research validated eight peptide barcodes designed for minimal detection bias and maximum sensitivity, featuring a streamlined workflow that reduces sample input requirements and hands-on time to under one hour. The system demonstrated a ten-fold dynamic range for detecting low-abundance proteins.
The combination of QSI's Platinum® Pro instrument with their protein Barcoding Kit offers advantages over DNA barcodes by providing direct quantitative readout of protein expression and localization. This advancement has potential applications in protein engineering, targeted drug delivery, and nucleic acid therapy development.
Quantum-Si (Nasdaq: QSI) ha pubblicato un nuovo preprint che dimostra l'integrazione del loro strumento da laboratorio Platinum® con la tecnologia di codifica a barre per proteine. Lo studio presenta un nuovo flusso di lavoro che migliora l'analisi multiplex di proteine con sensibilità e accessibilità superiori rispetto ai metodi tradizionali come la spettrometria di massa.
La ricerca ha convalidato otto codici a barre peptidici progettati per ridurre al minimo il bias di rilevamento e massimizzare la sensibilità, presentando un flusso di lavoro semplificato che riduce i requisiti di campione e il tempo di intervento a meno di un'ora. Il sistema ha dimostrato un intervallo dinamico dieci volte superiore per il rilevamento di proteine a bassa abbondanza.
La combinazione dello strumento Platinum® Pro di QSI con il loro Kit per la Codifica a Barre di Proteine offre vantaggi rispetto ai codici a barre del DNA, fornendo una lettura quantitativa diretta dell'espressione e della localizzazione delle proteine. Questo progresso ha potenziali applicazioni nell'ingegneria delle proteine, nella somministrazione mirata di farmaci e nello sviluppo di terapie a base di acidi nucleici.
Quantum-Si (Nasdaq: QSI) ha lanzado un nuevo preprint que demuestra la integración de su instrumento de laboratorio Platinum® con tecnología de codificación de proteínas. El estudio presenta un nuevo flujo de trabajo que mejora el análisis multiplex de proteínas con mayor sensibilidad y accesibilidad en comparación con métodos tradicionales como la espectrometría de masas.
La investigación validó ocho códigos de barras péptidos diseñados para minimizar el sesgo de detección y maximizar la sensibilidad, presentando un flujo de trabajo simplificado que reduce los requisitos de muestra y el tiempo de intervención a menos de una hora. El sistema demostró un rango dinámico diez veces mayor para detectar proteínas de baja abundancia.
La combinación del instrumento Platinum® Pro de QSI con su Kit de Codificación de Proteínas ofrece ventajas sobre los códigos de barras de ADN al proporcionar una lectura cuantitativa directa de la expresión y localización de proteínas. Este avance tiene aplicaciones potenciales en la ingeniería de proteínas, la administración dirigida de fármacos y el desarrollo de terapias de ácidos nucleicos.
Quantum-Si (Nasdaq: QSI)는 자사의 탁상형 Platinum® 기기와 단백질 바코딩 기술을 통합한 새로운 프리프린트를 발표했습니다. 이 연구는 질량 분석계와 같은 전통적인 방법에 비해 감도와 접근성을 개선한 다중 단백질 분석을 향상시키는 새로운 워크플로를 보여줍니다.
이 연구는 최소한의 검출 편향과 최대 감도를 위해 설계된 여덟 개의 펩타이드 바코드를 검증하였으며, 샘플 입력 요구 사항과 실시간 작업 시간을 한 시간 이하로 줄이는 간소화된 워크플로를 특징으로 합니다. 이 시스템은 저농도 단백질을 탐지하기 위한 10배의 동적 범위를 시연했습니다.
QSI의 Platinum® Pro 기기와 단백질 바코딩 키트의 조합은 단백질 발현 및 국소성을 직접적으로 정량적으로 측정할 수 있어 DNA 바코드에 비해 이점을 제공합니다. 이 발전은 단백질 공학, 표적 약물 전달 및 핵산 치료 개발에 잠재적인 응용 프로그램이 있습니다.
Quantum-Si (Nasdaq: QSI) a publié un nouveau pré-impression démontrant l'intégration de son instrument de paillasse Platinum® avec la technologie de codage des protéines. L'étude présente un nouveau flux de travail qui améliore l'analyse multiplexée des protéines avec une sensibilité et une accessibilité accrues par rapport aux méthodes traditionnelles comme la spectrométrie de masse.
La recherche a validé huit codes-barres peptidiques conçus pour minimiser le biais de détection et maximiser la sensibilité, avec un flux de travail simplifié qui réduit les exigences d'entrée de l'échantillon et le temps d'intervention à moins d'une heure. Le système a démontré une gamme dynamique multipliée par dix pour la détection de protéines à faible abondance.
La combinaison de l'instrument Platinum® Pro de QSI avec son Kit de Codage des Protéines offre des avantages par rapport aux codes-barres ADN en fournissant une lecture quantitative directe de l'expression et de la localisation des protéines. Cette avancée a des applications potentielles dans l'ingénierie des protéines, la délivrance ciblée de médicaments et le développement de thérapies à base d'acides nucléiques.
Quantum-Si (Nasdaq: QSI) hat ein neues Preprint veröffentlicht, das die Integration ihres Tischgeräts Platinum® mit der Protein-Barcoding-Technologie demonstriert. Die Studie zeigt einen neuartigen Workflow, der die multiplexierte Proteinanalyse mit verbesserter Empfindlichkeit und Zugänglichkeit im Vergleich zu traditionellen Methoden wie der Massenspektrometrie verbessert.
Die Forschung validierte acht Peptid-Barcodes, die so konzipiert sind, dass sie eine minimale Erkennungs-Bias und maximale Empfindlichkeit erzielen, und bietet einen vereinfachten Workflow, der die Anforderungen an die Probenmenge sowie die praktische Arbeitszeit auf unter eine Stunde reduziert. Das System zeigte einen zehnfachen Dynamikbereich zur Erkennung von Proteinen mit geringer Häufigkeit.
Die Kombination von QSIs Platinum® Pro Gerät mit ihrem Protein-Barcoding-Kit bietet Vorteile gegenüber DNA-Barcodes, indem sie eine direkte quantitative Erfassung von Proteinexpression und -lokalisation ermöglicht. Diese Fortschritte haben potenzielle Anwendungen in der Proteinengineering, zielgerichteten Medikamentenverabreichung und der Entwicklung von Nukleinsäuretherapien.
- Development of optimized workflow reducing sample processing time to less than one hour
- Validation of eight peptide barcodes with minimal detection bias
- Demonstrated ten-fold dynamic range for protein detection
- Direct quantitative readout capability for protein expression
- None.
Insights
The technological advancement in protein barcoding demonstrated by Quantum-Si represents a significant leap in proteomics research capabilities. The development of an optimized workflow requiring less than one hour of hands-on time, combined with a ten-fold dynamic range, addresses critical bottlenecks in protein analysis that have historically research productivity.
A key commercial advantage lies in the system's ability to function with reduced sample input requirements. This enhancement could translate to substantial cost savings for research institutions and potentially accelerate drug development timelines. The validation of eight peptide barcodes with minimized detection bias positions QSI's platform as a compelling alternative to traditional mass spectrometry approaches.
The direct quantitative readout capability for protein expression sets this technology apart from DNA barcoding methods, particularly valuable for companies developing nucleic acid-based therapeutics. This feature could drive adoption among pharmaceutical companies working on next-generation drug delivery systems.
The proteomics market context is important here - with a projected CAGR of 14.5% through 2030, QSI's technological advancement comes at an opportune time. The Platinum® Pro instrument's enhanced capabilities could help capture market share in the rapidly growing
The streamlined workflow represents a significant competitive advantage, potentially lowering the barrier to entry for smaller research institutions while maintaining appeal to larger pharmaceutical companies. The technology's application in targeted drug delivery and nucleic acid therapy development aligns with high-growth segments of the biotech market.
While this preprint release itself isn't a direct revenue generator, it validates QSI's technology platform and could accelerate market adoption, particularly in the lucrative drug development sector where efficient protein analysis tools are in high demand.
Protein barcoding has emerged as a powerful tool for multiplexed protein selection, analysis, and tracking, enabling advanced insights into proteomics research. Traditional detection methods, such as mass spectrometry, often face challenges related to quantification, cost, and accessibility. Quantum-Si addresses these challenges with a groundbreaking workflow that enhances the precision and sensitivity of protein barcoding, expanding its utility across applications like protein engineering, targeted drug delivery, and nucleic acid therapy development.
Study Highlights:
- Validation of Peptide Barcodes: Development and validation of eight peptide barcodes designed to minimize detection bias and maximize sensitivity.
- Streamlined Workflow: Optimized expression constructs and process that reduced the sample input requirement and the hands-on time to less than one hour.
- Dynamic Range: Demonstrated ten-fold dynamic range, enabling robust detection of low abundance proteins.
“Combining our Platinum® Pro instrument with the recently launched protein Barcoding Kit enables unmatched sensitivity and accessibility in proteomics research,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “This study serves as a foundation for implementing protein barcoding workflows and NGPS across a range of applications, driving advancements in protein characterization and targeted therapeutic strategies. It aligns with our mission to revolutionize protein sequencing and expand its applications to deliver significant breakthroughs in research and drug development.”
By leveraging Quantum-Si’s single-molecule NGPS technology, the study also underscores the advantages of protein barcode sequencing compared to DNA barcodes which are limited in their ability to directly detect successful translation. Next-Generation Protein Sequencing™ provides a direct quantitative readout of protein expression and localization, offering a more precise method for development of nucleic acid delivery vectors like lipid nano-particles and adeno associated viruses.
To read the preprint, visit: Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking | Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108165603/en/
Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What are the key features of Quantum-Si's new protein barcoding technology?
How does QSI's protein barcoding differ from traditional DNA barcoding methods?
What applications can benefit from Quantum-Si's protein barcoding technology?
What advantages does Quantum-Si's Platinum® Pro instrument offer for protein analysis?
